SOW
PLX icon

State of Wyoming’s Protalix BioTherapeutics PLX Stock Holding History

State of Wyoming’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Buy
+59,179
New +$125K 0.01% 1246
2025
Q4 		– Sell
-39,018
Closed -$86.6K – 2034
2025
Q3 		$86.6K Buy
+39,018
New +$63.5K 0.01% 1350
2023
Q4 		– Sell
-41,268
Closed -$68.5K – 1763
2023
Q3 		$68.5K Buy
+41,268
New +$74.1K 0.01% 1104

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State of Wyoming's PLX Position: Q2 2026 in Review

State of Wyoming opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 59,179 shares worth $138K. The stake represents 0.01% of the portfolio and ranks #1246 among its holdings. This is a return to the name: State of Wyoming previously reported a position in PLX as recently as Q3 2025.

State of Wyoming first reported a position in PLX in Q3 2023 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • State of Wyoming held 59,179 shares of Protalix BioTherapeutics worth $138K as of Q2 2026.
  • Protalix BioTherapeutics was a new State of Wyoming position in Q2 2026.
  • Protalix BioTherapeutics made up 0.01% of State of Wyoming's portfolio in Q2 2026, its #1246 holding.
  • State of Wyoming first reported a position in Protalix BioTherapeutics in Q3 2023 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.